AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24918563 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 83
Study 24918563 — intervention group
Group type: COMPARATOR
Intervention: Active treatment gel
Number of subjects: 83
Study 23092876 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous costimulated T-cell product administered on day 2
Number of subjects: 42
Study 23092876 — intervention group
Group type: COMPARATOR
Intervention: T cells administered on day 90
Number of subjects: 42
Study 19852290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Zhuanggu Granule (BZG)
Number of subjects: 377
Study 19852290 — intervention group
Group type: COMPARATOR
Intervention: Premarin plus Depogeston (WM)
Number of subjects: 377
Study 19852290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BZG and WM
Number of subjects: 377
Study 18080956 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Cochrane Review abstracts in Spanish
Number of subjects: 0
Study 18080956 — intervention group
Group type: COMPARATOR
Intervention: Reading Cochrane Review abstracts in English
Number of subjects: 0
Study 18080956 — intervention group
Group type: COMPARATOR
Intervention: Reading in English
Number of subjects: 0
Study 14647963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (50‐1200 mg/day)
Number of subjects: 1422
Study 14647963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (mean daily doses below 400 mg/day)
Number of subjects: 1422
Study 14647963 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (1‐year studies)
Number of subjects: 1422
Study 11589262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg to 0.4 mg
Number of subjects: 417
Study 11589262 — intervention group
Group type: COMPARATOR
Intervention: Branded Pravastatin 10 mg to 40 mg
Number of subjects: 417
Study 11589262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 417
Study 11589262 — intervention group
Group type: COMPARATOR
Intervention: Branded Pravastatin
Number of subjects: 417
Study 11589262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin and Branded Pravastatin
Number of subjects: 417
Study 9700516 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (M = 26.92 mg/day = 0.78 mg/kg/day)
Number of subjects: 26
Study 9700516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9700516 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 26
Study 8005277 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block anesthesia
Number of subjects: 101
Study 8005277 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 101
Study 8005277 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 101
Study 2680611 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex-scanning
Number of subjects: 69
Study 2680611 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 69
Study 2680611 — intervention group
Group type: COMPARATOR
Intervention: Conventional arch angiography
Number of subjects: 69
Study 22305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 5
Study 22305 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (600 mg in 1 dl of isotonic saline)
Number of subjects: 5
Study 30343874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-promoting interventions
Number of subjects: 144
Study 30343874 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care overnight
Number of subjects: 144
Study 28045625 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy (anastrozole, exemestane, or letrozole)
Number of subjects: 341
Study 28045625 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant aromatase inhibitor therapy
Number of subjects: 341
Study 28045625 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 341
Study 26204566 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) of the motor cortex (C3)
Number of subjects: 0
Study 26204566 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 23795311 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity navigation services
Number of subjects: 835
Study 23795311 — intervention group
Group type: COMPARATOR
Intervention: Low intensity navigation services
Number of subjects: 835
Study 23795311 — intervention group
Group type: EXPERIMENTAL
Intervention: Public insurance patients
Number of subjects: 835
Study 23795311 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighbor Island patients
Number of subjects: 835
Study 20707872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health program including fluoride varnish applied twice per year for 2 years, advocacy for water consumption and daily tooth cleaning with toothpaste, community dental health promotion, and training for primary health care workers in preventive dental care.
Number of subjects: 666
Study 19539184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein supplementation during hemodialysis and peritoneal dialysis
Number of subjects: 49
Study 19539184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 49
Study 19539184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein supplementation
Number of subjects: 49
Study 19539184 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (protein supplementation and control)
Number of subjects: 49
Study 16894061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 18
Study 16894061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15327558 — intervention group
Group type: EXPERIMENTAL
Intervention: HP cream and adapalene 0.1% gel (group HP + A)
Number of subjects: 52
Study 15327558 — intervention group
Group type: COMPARATOR
Intervention: BP cream and adapalene 0.1% gel (group BP + A)
Number of subjects: 52
Study 11009278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin low molecular weight heparin
Number of subjects: 0
Study 11009278 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 9015035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (6 mg)
Number of subjects: 11
Study 9015035 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (8 mg)
Number of subjects: 11
Study 8112199 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 60
Study 8112199 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 60
Study 3526143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside therapy (Cronassial, 40 mg daily)
Number of subjects: 28
Study 3526143 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study 31144070 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise associated with active PBM (808 nm, 100 mW, 7 points each side, 56 J total)
Number of subjects: 62
Study 31144070 — intervention group
Group type: COMPARATOR
Intervention: Exercise associated with placebo PBM
Number of subjects: 62
Study 31144070 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBM group
Number of subjects: 62
Study 31144070 — intervention group
Group type: COMPARATOR
Intervention: Placebo PBM group
Number of subjects: 62
Study 31091576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Propofol (SP group)
Number of subjects: 200
Study 31091576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Propofol (CP group)
Number of subjects: 200
Study 31091576 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine + Sevoflurane (SS group)
Number of subjects: 200
Study 31091576 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine + Sevoflurane (CS group)
Number of subjects: 200
Study 28273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean black raspberry (KBR) consumption for four weeks
Number of subjects: 0
Study 28273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urinary glycine and N-phenylacetylglycine (PAG)
Number of subjects: 0
Study 28273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urinary adenine
Number of subjects: 0
Study 28273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-metabolite set (glycine and PAG)
Number of subjects: 0
Study 28273855 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave-one-out cross-validation
Number of subjects: 0
Study 25956910 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 35
Study 25956910 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 23089290 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributional information with strong category cues and robust category learning
Number of subjects: 0
Study 23089290 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributional information with sparser cues and consistent gaps
Number of subjects: 0
Study 21074334 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided radiation therapy (IGRT) using intraprostatic fiducials and Varian's Offline Review image analysis package.
Number of subjects: 0
Study 21074334 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRT credentialing process across multiple sites.
Number of subjects: 0
Study 19200695 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-based psychotherapy
Number of subjects: 80
Study 16686556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic gymnastics program (16 weeks, 3 lessons per week, 40 minutes each)
Number of subjects: 29
Study 16686556 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular school schedule)
Number of subjects: 29
Study 15471831 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET
Number of subjects: 37
Study 11889646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain descriptors and indexes from the Italian Pain Questionnaire
Number of subjects: 332
Study 11889646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation of quality of life (QOL) from a categorical scale
Number of subjects: 332
Study 11889646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed anxiety and/or depression
Number of subjects: 332
Study 10771818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin crystals in neutrophils (CP) in cases of septicaemia
Number of subjects: 143
Study 10771818 — intervention group
Group type: COMPARATOR
Intervention: Bilirubin crystals in neutrophils (CP) in cases of Haemolytic Disease of Newborn (HDN)
Number of subjects: 143
Study 7890434 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemodiafiltration
Number of subjects: 72
Study 3213064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for 2 weeks
Number of subjects: 0
Study 3213064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for 4 weeks
Number of subjects: 0
Study 3213064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 4 weeks
Number of subjects: 0
Study 3213064 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Acupuncture and Physical Therapy)
Number of subjects: 0
Study 30371925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg orally)
Number of subjects: 124
Study 30371925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg IV bolus, followed by 0.5 µg/kg/h infusion)
Number of subjects: 124
Study 30371925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin and Dexmedetomidine (combined treatment)
Number of subjects: 124
Study 30371925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 124
Study 27411760 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during non-stress test (NST)
Number of subjects: 60
Study 27411760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 60
Study 27411760 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during NST
Number of subjects: 60
Study 24412145 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM device on and moving from the immediate post-operative period
Number of subjects: 160
Study 24412145 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM device on and stationary at 90 degree flexion for the first night and then moving throughout the rest of their stay
Number of subjects: 160
Study 24412145 — intervention group
Group type: COMPARATOR
Intervention: No CPM
Number of subjects: 160
Study 21884017 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 or 90 mg daily
Number of subjects: 34701
Study 21884017 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 150 mg daily
Number of subjects: 34701
Study 21884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 34701
Study 21884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 34701
Study 21884017 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in blood pressure from months 0 to 4
Number of subjects: 34701
Study 20099399 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor strategy
Number of subjects: 903
Study 20099399 — intervention group
Group type: COMPARATOR
Intervention: NNRTI strategy
Number of subjects: 903
Study 20099399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative adherence
Number of subjects: 903
Study 18164829 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) + thalidomide
Number of subjects: 156
Study 18164829 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 156
Study 15959841 — intervention group
Group type: EXPERIMENTAL
Intervention: NT 201
Number of subjects: 304
Study 15959841 — intervention group
Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 304
Study 11738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Monothermal warm air caloric test (MWAT)
Number of subjects: 86
Study 11738688 — intervention group
Group type: COMPARATOR
Intervention: Bithermal air caloric test (BAT)
Number of subjects: 86
Study 11738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Monothermal cold air caloric test (MCAT)
Number of subjects: 86
Study 9737815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eprosartan (300 mg) under fasting conditions
Number of subjects: 18
Study 9737815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eprosartan (300 mg) following a high-fat breakfast
Number of subjects: 18
Study 9737815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eprosartan (20 mg)
Number of subjects: 18
Study 8296748 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg every day
Number of subjects: 135
Study 8296748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 3046309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet
Number of subjects: 0
Study 3046309 — intervention group
Group type: COMPARATOR
Intervention: Seventh-day Adventist vegetarians
Number of subjects: 0
Study 31407238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 0
Study 31407238 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 0
Study 29136037 — intervention group
Group type: EXPERIMENTAL
Intervention: IV VRC01 (40 mg/kg loading dose followed by five 20 mg/kg doses every 4 weeks)
Number of subjects: 88
Study 29136037 — intervention group
Group type: EXPERIMENTAL
Intervention: IV VRC01 (30 mg/kg doses every 8 weeks)
Number of subjects: 88
Study 29136037 — intervention group
Group type: EXPERIMENTAL
Intervention: IV VRC01 (10 mg/kg doses every 8 weeks)
Number of subjects: 88
Study 29136037 — intervention group
Group type: EXPERIMENTAL
Intervention: SC VRC01 (5 mg/kg every 2 weeks)
Number of subjects: 88
Study 29136037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 23966118 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time awake
Number of subjects: 40
Study 23966118 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced time spent in stage 1 sleep
Number of subjects: 40
Study 23966118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep efficiency
Number of subjects: 40
Study 23966118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep time
Number of subjects: 40
Study 21167685 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Number of subjects: 31
Study 21167685 — intervention group
Group type: COMPARATOR
Intervention: Casein formula; 35 kcal/kg/d and 1.2 g of protein/kg/d for 5 days
Number of subjects: 31
Study 19183414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 109
Study 19183414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 19183414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 109
Study 17401538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX) 4 mg twice a day for 4 days preceded by 2 mg twice a day for 2 days
Number of subjects: 12
Study 17401538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17401538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 12
Study 15527198 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi-therapy (nine sessions over two menstrual cycles)
Number of subjects: 46
Study 15527198 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 46
Study 11137652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambisome (amphotericin B lipid complex) at a dose of 15mg/kg body weight infused over 2h as a single dose
Number of subjects: 34
Study 11137652 — intervention group
Group type: COMPARATOR
Intervention: amphotericin B deoxycholate at a dose of 1mg/kg body infused for 2h for 20 days
Number of subjects: 34
Study 9754723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (acid suppression)
Number of subjects: 0
Study 9754723 — intervention group
Group type: COMPARATOR
Intervention: Placebo/ranitidine
Number of subjects: 0
Study 9754723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 7812019 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation after proximal femoral fracture
Number of subjects: 200
Study 7812019 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 200
Study 2684085 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 250
Study 2684085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 250
Study 2684085 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride plus clinical management
Number of subjects: 250
Study 2684085 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus clinical management
Number of subjects: 250
Study 31826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (6 times a week)
Number of subjects: 332
Study 31826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (3 times a week)
Number of subjects: 332
Study 31826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Daily Trial)
Number of subjects: 332
Study 31826326 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (Nocturnal Trial)
Number of subjects: 332
Study 30611722 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided treatment
Number of subjects: 268
Study 30611722 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268
Study 30611722 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP reduction
Number of subjects: 268
Study 30611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving NT-proBNP goal
Number of subjects: 268
Study 29241487 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2947
Study 29241487 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2947
Study 25938245 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized spatial navigation training
Number of subjects: 15
Study 25938245 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 15
Study 23216554 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial education program (4 sessions, 120 minutes each, once a week for 4 weeks)
Number of subjects: 75
Study 23216554 — intervention group
Group type: COMPARATOR
Intervention: Routine program at private education and rehabilitation centre (control group)
Number of subjects: 75
Study 21462185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 100
Study 21462185 — intervention group
Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 100
Study 19022794 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 82
Study 19022794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16469857 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food (cocoa beverage)
Number of subjects: 36
Study 16469857 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-free food (milk)
Number of subjects: 36
Study 16183679 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated recombinant factor VII (rFVIIa)
Number of subjects: 20
Study 16183679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12825133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha2b + Cyclosporin A (200 mg daily for the first 4 weeks and 100 mg daily for the following 20 weeks)
Number of subjects: 120
Study 12825133 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha2b + Cyclosporin A
Number of subjects: 120
Study 12825133 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha2b (monotherapy)
Number of subjects: 120
Study 9974084 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 43